Just starting a fun thread! (posted also in the RAD thread).
I was thinking about investing in a promising Paul Hopper Biotech.
RAD and CHM have similar market caps, are in the cancer space, with multiple IP opportunities, similar cash burn with similar cash on hand and at a similar age in its corporate evolution. If you had to choose only one investment, which would it be and why?
Paul Hopper IP opportunists CHM VS RAD
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.1¢ |
Change
-0.003(8.82%) |
Mkt cap ! $26.40M | |||
| Open | High | Low | Value | Volume |
| 3.4¢ | 3.4¢ | 2.9¢ | $222.5K | 7.171M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5 | 3.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.2¢ | 125000 | 1 |
View Market Depth
| Last trade - 16.10pm 19/04/2024 (20 minute delay) ? |
|
|||||
|
Last
3.1¢ |
Change
-0.003 ( 11.4 %) |
||||
| Open | High | Low | Volume | ||
| 3.4¢ | 3.4¢ | 2.9¢ | 4181329 | ||
| Last updated 15.30pm 19/04/2024 ? | |||||
| CHM (ASX) Chart |